Vishnu Nayak Badavath

Dr. Vishnu Nayak Badavath

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Closed access
SGSuresh Gangadevi
Suresh Gangadevi
VBVishnu Nayak Badavath
Vishnu Nayak Badavath
ATAbhishek Thakur
Abhishek Thakur
NYNa Yin
Na Yin
SJSteven De Jonghe
Steven De Jonghe
GBGalia Blum
Galia Blum

4 December 2015 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
VBVishnu Nayak Badavath
Vishnu Nayak Badavath
IBİpek Baysal
İpek Baysal
GUGulberk Ucar
Gulberk Ucar
BSBarij Nayan Sinha
Barij Nayan Sinha
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash

17 November 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
VBVishnu Nayak Badavath
Vishnu Nayak Badavath
AKAkhil Kumar
Akhil Kumar
PSPralok Kumar Samanta
Pralok Kumar Samanta
SMSiddhartha Maji
Siddhartha Maji
ADAnik Das
Anik Das
ASANIK SEN
ANIK SEN
SARS-COV-2, the novel coronavirus and root of global pandemic COVID-19 caused a severe health threat throughout the world. Lack of specific treatments raised an effort to find potential inhibitors for the viral proteins. The recently invented crystal structure of SARS-CoV-2 main protease (Mpro) and its key role in viral replication; non-resemblance to any human protease makes it a perfect target for inhibitor research. This article reports a computer-aided drug design (CADD) approach for the screening of 118 compounds with 16 distinct heterocyclic moieties in comparison with 5 natural products and 7 repurposed drugs. Molecular docking analysis against Mpro protein were performed finding isatin linked with a oxidiazoles (A2 and A4) derivatives to have the best docking scores of −11.22 kcal/mol and −11.15 kcal/mol respectively. Structure-activity relationship studies showed a good comparison with a known active Mpro inhibitor and repurposed drug ebselen with an IC50 value of −0.67 μM. Molecular Dynamics (MD) simulations for 50 ns were performed for A2 and A4 supporting the stability of the two compounds within the binding pocket, largely at the S1, S2 and S4 domains with high binding energy suggesting their suitability as potential inhibitors of Mpro for SARS-CoV-2. Graphical Abstract Communicated by Ramaswamy H. Sarma

1 November 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VBVishnu Nayak Badavath
Vishnu Nayak Badavath
SCS. Ciftci-Yabanoglu
S. Ciftci-Yabanoglu
Surender Singh JadavSurender Singh Jadav
Surender Singh Jadav
MJMonika Jagrat
Monika Jagrat
BSBarij N. Sinha
Barij N. Sinha
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash

1 April 2015 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Surender Singh JadavSurender Singh Jadav
Surender Singh Jadav
SKSuzanne Kaptein
Suzanne Kaptein
ATAjaykumar Timiri
Ajaykumar Timiri
TBTine De Burghgraeve
Tine De Burghgraeve
VBVishnu Nayak Badavath
Vishnu Nayak Badavath
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash

1 August 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MMManohar Mantipally
Manohar Mantipally
MGMadhusudhana Reddy Gangireddy
Madhusudhana Reddy Gangireddy
RGRambabu Gundla
Rambabu Gundla
VBVishnu Nayak Badavath
Vishnu Nayak Badavath
SMSanthosh Reddy Mandha
Santhosh Reddy Mandha
VMVenkatanarayana Chowdary Maddipati
Venkatanarayana Chowdary Maddipati